Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients

Anne‐Marie Taburet, Christophe Piketty, Corine Chazallon, +6

Antimicrobial Agents and Chemotherapy

Antiviral CompoundHuman RetrovirusImmunologyPharmacologyResistance Mutation (Virology) +12

Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies

Eva Germovsek, Irja Lutsar, Karin Kipper, +29

Journal of Antimicrobial Chemotherapy

Successful implementation of a low-cost method for enumerating CD4+ T lymphocytes in resource-limited settings

Serge Diagbouga, Corine Chazallon, Michel D. Kazatchkine, +8

AIDS

Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial

Irja Lutsar, Corine Chazallon, Ursula Trafojer, +25

PLoS ONE

Current management of late onset neonatal bacterial sepsis in five European countries

Irja Lutsar, Corine Chazallon, Francesca Ippolita Calò Carducci, +18

European Journal of Pediatrics

NeonatologyAntibioticsHealthcare-associated InfectionEuropean CountriesPediatrics +6

Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial

Thomas Maitre, Maryline Bonnet, Alexandra Calmy, +18

Trials

Renal Function in Antiretroviral-Experienced Patients treated with Tenofovir Disoproxil Fumarate associated with Atazanavir/ritonavir

Laurence Gérard, Corine Chazallon, Anne‐Marie Taburet, +3

Antiviral Therapy

Gag Mutations Can Impact Virological Response to Dual-Boosted Protease Inhibitor Combinations in Antiretroviral-Naive HIV-Infected Patients

Lucile Larrouy, Corine Chazallon, Roland Landman, +12

Antimicrobial Agents and Chemotherapy

Influence of Alpha-1 Glycoprotein Acid Concentrations and Variants on Atazanavir Pharmacokinetics in HIV-Infected Patients Included in the ANRS 107 Trial

Aurélie Barrail‐Tran, France Mentré, Claudine Cosson, +5

Antimicrobial Agents and Chemotherapy

Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial

Nathalie De Castro, Olivier Marcy, Corine Chazallon, +144

The Lancet Infectious Diseases

Reflate Tb 2Pulmonary TuberculosisStandard Dose RaltegravirTreatment And PreventionTuberculosis Prevention +7